U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H32O6S
Molecular Weight 436.562
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of Rivenprost free acid

SMILES

COCC1=CC(C[C@H](O)\C=C\[C@H]2[C@H](O)CC(=O)[C@@H]2CCSCCCC(O)=O)=CC=C1

InChI

InChIKey=ORSJUPRAHPZYRL-XHTUOEPPSA-N
InChI=1S/C23H32O6S/c1-29-15-17-5-2-4-16(12-17)13-18(24)7-8-19-20(22(26)14-21(19)25)9-11-30-10-3-6-23(27)28/h2,4-5,7-8,12,18-21,24-25H,3,6,9-11,13-15H2,1H3,(H,27,28)/b8-7+/t18-,19-,20-,21-/m1/s1

HIDE SMILES / InChI

Molecular Formula C23H32O6S
Molecular Weight 436.562
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 1
Optical Activity UNSPECIFIED

Rivenprost (ONO-4819) is a potent and selective EP4 receptor agonist. This compound can increase bone formation by stimulating osteoblast differentiation and function, possibly by modulating mesenchymal cell differentiation. Rivenprost has also been studied for its potential to prevent bone loss (in osteoporosis) and stabilize bone implants. Combined with risedronate, rivenprost may be an effective treatment for osteoporosis. A phase II study evaluating rivenprost in ulcerative colitis was terminated in 2009.

Approval Year

PubMed

PubMed

TitleDatePubMed
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.
2002 Apr 2
Patents
Substance Class Chemical
Created
by admin
on Wed Apr 02 16:57:57 GMT 2025
Edited
by admin
on Wed Apr 02 16:57:57 GMT 2025
Record UNII
T7XW73LKW4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
4-[[2-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-buten-1-yl]-5-oxocyclopentyl]ethyl]thio]butanoic acid
Preferred Name English
Rivenprost free acid
Common Name English
Butanoic acid, 4-[[2-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-buten-1-yl]-5-oxocyclopentyl]ethyl]thio]-
Systematic Name English
Butanoic acid, 4-[[2-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-butenyl]-5-oxocyclopentyl]ethyl]thio]-
Systematic Name English
Code System Code Type Description
FDA UNII
T7XW73LKW4
Created by admin on Wed Apr 02 16:57:57 GMT 2025 , Edited by admin on Wed Apr 02 16:57:57 GMT 2025
PRIMARY
CAS
256382-23-7
Created by admin on Wed Apr 02 16:57:57 GMT 2025 , Edited by admin on Wed Apr 02 16:57:57 GMT 2025
PRIMARY
EPA CompTox
DTXSID301102270
Created by admin on Wed Apr 02 16:57:57 GMT 2025 , Edited by admin on Wed Apr 02 16:57:57 GMT 2025
PRIMARY
PUBCHEM
9824353
Created by admin on Wed Apr 02 16:57:57 GMT 2025 , Edited by admin on Wed Apr 02 16:57:57 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY